Cargando…
Resveratrol Modulates the Topoisomerase Inhibitory Potential of Doxorubicin in Human Colon Carcinoma Cells
Resveratrol (RSV) is currently being widely discussed as potentially useful for anticancer therapy in combination with classical chemotherapeutics, e.g., the topoisomerase II (TOP II) poison doxorubicin (DOX). However, there is still a lack of knowledge of possible interference at the target enzyme,...
Autores principales: | Schroeter, Anika, Marko, Doris |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6271354/ https://www.ncbi.nlm.nih.gov/pubmed/25470274 http://dx.doi.org/10.3390/molecules191220054 |
Ejemplares similares
-
Modulation of doxorubicin cytotoxicity by resveratrol in a human breast cancer cell line
por: Osman, Abdel-Moneim M, et al.
Publicado: (2012) -
Doxorubicin and resveratrol co-delivery nanoparticle to overcome doxorubicin resistance
por: Zhao, Yuan, et al.
Publicado: (2016) -
Resveratrol reverses multidrug resistance in human breast cancer doxorubicin-resistant cells
por: HUANG, FANG, et al.
Publicado: (2014) -
Simvastatin-induced compartmentalisation of doxorubicin sharpens up nuclear topoisomerase II inhibition in human rhabdomyosarcoma cells
por: Werner, Martin, et al.
Publicado: (2013) -
Type IIB DNA topoisomerase is downregulated by trastuzumab and doxorubicin to synergize cardiotoxicity
por: Jiang, Jiangsong, et al.
Publicado: (2017)